Fuyuhiko Motoi

20PUBLICATIONS
59CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsRadiation therapyPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Nov 21, 2025
Real-world outcomes of anthracycline and taxane-based perioperative breast cancer therapy using the Japanese electronic medical record database.

Masaaki Kawai, Tomoko Kazato, Wakana Kiyosaki

|Sep 02, 2025
ASO Visual Abstract: Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer.

Yuya Ashitomi, Fuyuhiko Motoi, Atsushi Oba

|Sep 01, 2025
ASO Author Reflections: How to Evaluate CA19-9 Response to Neoadjuvant Treatment for Resectable Pancreatic Cancer?: Reduced Value or Reduction Rate?

Fuyuhiko Motoi, Yuya Ashitomi

|Sep 01, 2025
Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer.

Yuya Ashitomi, Fuyuhiko Motoi, Atsushi Oba

|Aug 28, 2025
Treatment Outcomes in Patients Receiving Carbon-Ion Radiotherapy Versus Hepatectomy for Hepatocellular Carcinoma (≥4 cm): A Retrospective Study in Japan.

Keita Maki, Hiroaki Haga, Tomohiro Katsumi

|Jul 03, 2025
Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter retrospective study.

Tomohisa Yamamoto, Toshio Shimokawa, Masamichi Hayashi

Pageof 4

Frequent Collaborators

4 joint publications

Takanori Morikawa

4 joint publications

Kei Nakagawa

4 joint publications

Masamichi Mizuma

4 joint publications

Tatsuo Hata